Jun. 13 at 1:23 PM
RBC Capital⬆️
$XENE PT to
$57 from
$55, reit'd its OP and said, "Analysis Shows Strong Historical Ph.Il to Ph.III Translatability For Epilepsy Drugs"
$BHVN $NBIX $JAZZ
RBC added, "Our analysis of historical focal onset efficacy studies shows high translatability between ph.Il and ph.Ill on seizure reductions and responder rate, suggesting a good likelihood azetukalner's ph.Ill data early next year should mostly recapitulate their promising ph.Il data.
Even under conservative assumptions, azetukalner's efficacy, novel Kv7 MOA, rapid onset, and potential mood benefits, in a space dominated by polypharmacy, should be highly competitive and give the drug an impt,
$1.2B (RBCe) future role.
Therapeutic window remains key, though having two
tested dose options should help real-world pt management. Shares appear to underappreciate azetukalner's opportunity; increasing tgt to
$57 on higher PoS and see favorable stock setup into ph.Ill data."
